Haha. Dragging my heels, I know.
I’ll have to lift my game.
I missed another, posted on the trial site 2 days earlier, that your people may also be interested in.
The trial above (NCT04814719):
The purpose of this study is to measure the duration of treatment effect and response to re-treatment with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with placebo in adult participants with knee osteoarthritis (OA) pain.
The one I missed (NCT04809376):
Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium Versus Placebo in Participants With Knee Osteoarthritis Pain
https://clinicaltrials.gov/ct2/show/NCT04809376?term=Pentosan&draw=2&rank=5
The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee osteoarthritis pain.
Pfizer's Tanezumab receives almost unanimous rejection by FDA Adcom, page-18
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
-0.010(3.45%) |
Mkt cap ! $97.94M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.5¢ | 27.5¢ | $444.5K | 1.482M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19907 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 3330 | 1 |
View Market Depth
| Last trade - 16.10pm 02/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |